Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Change in Cash (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Change in Cash for 17 consecutive years, with -$5.5 billion as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 324.45% to -$5.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$129.0 million through Dec 2025, up 88.99% year-over-year, with the annual reading at -$129.0 million for FY2025, 88.99% up from the prior year.
  • Change in Cash for Q4 2025 was -$5.5 billion at Bristol Myers Squibb, down from $3.1 billion in the prior quarter.
  • The five-year high for Change in Cash was $4.0 billion in Q4 2023, with the low at -$5.5 billion in Q4 2025.
  • Average Change in Cash over 5 years is -$237.8 million, with a median of -$100.5 million recorded in 2021.
  • The sharpest move saw Change in Cash skyrocketed 594.42% in 2021, then tumbled 2230.26% in 2022.
  • Over 5 years, Change in Cash stood at $437.0 million in 2021, then surged by 213.04% to $1.4 billion in 2022, then soared by 188.82% to $4.0 billion in 2023, then plummeted by 37.89% to $2.5 billion in 2024, then tumbled by 324.45% to -$5.5 billion in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$5.5 billion, $3.1 billion, and $1.7 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.